DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

in subcellular fractions of mouse brain. Proc Natl Acad Sci
USA, 1971, 68:1742–1747.
Gonzalez JP, Brogden RN. Naltrexone. A review of its pharmacodynamic
and pharmacokinetic properties and therapeutic
efficacy in the management of opioid dependence. Drugs,
1988, 35:192–213.
Gourlay GK, Cherry DA, Cousins MJ. A comparative study of
the efficacy and pharmacokinetics of oral methadone and morphine
in the treatment of severe pain in patients with cancer.
Pain, 1986, 25:297–312.
Greenwood-Van Meerveld B. Emerging drugs for postoperative
ileus. Expert Opin Emerg Drugs, 2007, 12:619–626.
Gupta A, Decaillot FM, Devi LA. Targeting opioid receptor heterodimers:
strategies for screening and drug development.
Aaps J, 2006, 8:E153–E159.
Haile CN, Kosten TA, Kosten TR. Pharmacogenetic treatments
for drug addiction: alcohol and opiates. Am J Drug Alcohol
Abuse, 2008, 34:355–381.
Hamza M, Dionne RA. Mechanisms of non-opioid analgesics
beyond cyclooxygenase enzyme inhibition. Curr Mol
Pharmacol, 2009, 2:1–14.
Hartrick CT, Hartrick KA. Extended-release epidural morphine
(DepoDur): Review and safety analysis. Expert Rev Neurother,
2008, 8:1641–1648.
Hawryluk GWJ, Rowland J, Kwon BK, et al. Protection and
repair of the injured spinal cord: a review of completed, ongoing,
and planned clinical trials for acute spinal cord injury.
Neurosurg Focus, 2008, 25:E14.
Heishman SJ, Stitzer ML, Bigelow GE, Liebson IA. Acute opioid
physical dependence in postaddict humans: Naloxone dose
effects after brief morphine exposure. J Pharmacol Exp Ther,
1989, 248:127–134.
Henriksen G, Willoch F. Imaging of opioid receptors in the central
nervous system. Brain, 2008, 131:1171–1196.
Hoffman JR, Reynolds S. Comparison of nitroglycerin, morphine
and furosemide in treatment of presumed pre-hospital
pulmonary edema. Chest, 1987, 92:586–593.
Hook V, Funkelstein L, Lu D, et al. Proteases for processing
proneuropeptides into peptide neurotransmitters and hormones.
Annu Rev Pharmacol Toxicol, 2008, 48:393–423.
Hughes J, Smith TW, Kosterlitz HW, et al. Identification of two
related pentapeptides from the brain with potent opiate agonist
activity. Nature, 1975, 258:577–580. International
Association for the Study of Pain. Management of Acute Pain:
A Practical Guide. IASP Publications, Seattle, WA, 1992.
Johnson MA, Woodcock AA, Geddes DM. Dihydrocodeine for
breathlessness in “pink puffers.” Br Med J (Clin Res Ed), 1983,
286:675–677.
Kane BE, Svensson B, Ferguson DM. Molecular recognition of
opioid receptor ligands. AAPS J, 2006, 8:E126–E137.
Karavelis A, Foroglou G, Selviaridis P, Fountzilas G.
Intraventricular administration of morphine for control of
intractable cancer pain in 90 patients. Neurosurgery, 1996,
39:57–61; discussion 61–52.
Karlsson MO, Dahlstrom B, Neil A. Characterization of highaffinity
binding sites for the antitussive [3H]noscapine in
guinea pig brain tissue. Eur J Pharmacol, 1988, 145:
195–203.
King T, Ossipov MH, Vanderah TW, et al. Is paradoxical pain
induced by sustained opioid exposure an underlying mechanism
of opioid antinociceptive tolerance? Neurosignals, 2005,
14:194–205.
Koch T, Widera A, Bartzsch K, et al. Receptor endocytosis counteracts
the development of opioid tolerance. Mol Pharmacol,
2005, 67:280–287.
Koob GF, Bloom FE. Cellular and molecular mechanisms of
drug dependence. Science, 1988, 242:715–723.
Kreek MJ, Koob GF. Drug dependence: Stress and dysregulation
of brain reward pathways. Drug Alcohol Depend, 1998,
51:23–47.
Kreek MJ, LaForge KS, Butelman E. Pharmacotherapy of addictions.
Nat Rev Drug Discov, 2002, 1:710–726.
Kress HG, Oronska A, Kaczmarek Z, et al. Efficacy and tolerability
of intranasal fentanyl spray 50 to 200 μg for breakthrough
pain in patients with cancer: A phase III,
multinational, randomized, double-blind, placebo-controlled,
crossover trial with a 10-month, open-label extension treatment
period. Clin Ther, 2009, 31:1177–1191.
Kromer W. Endogenous and exogenous opioids in the control of
gastrointestinal motility and secretion. Pharmacol Rev, 1988,
40:121–162.
Krupnick JG, Benovic JL. The role of receptor kinases and
arrestins in G protein-coupled receptor regulation. Annu Rev
Pharmacol Toxicol, 1998, 38:289–319.
Lai J, Porreca F, Hunter JC, Gold MS. Voltage-gated sodium
channels and hyperalgesia. Annu Rev Pharmacol Toxicol,
2004, 44:371–397.
Lalley PM. Opioidergic and dopaminergic modulation of respiration.
Respir Physiol Neurobiol, 2008, 164:160–167.
Larson MD. Mechanism of opioid-induced pupillary effects.
Clin Neurophysiol, 2008, 119:1358–1364.
Latremoliere A, Woolf CJ. Central sensitization: A generator of
pain hypersensitivity by central neural plasticity. J Pain, 2009,
10:895–926.
Levine JD, Gordon NC, Smith R, McBryde R. Desipramine
enhances opiate postoperative analgesia. Pain, 1986, 27: 45–49.
Lewis KS, Han NH. Tramadol: A new centrally acting analgesic.
Am J Health Syst Pharm, 1997, 54:643–652.
Lindow SW, Hendricks MS, Nugent FA, et al. Morphine suppresses
the oxytocin response in breast-feeding women.
Gynecol Obstet Invest, 1999, 48:33–37.
Lyss AP, Portenoy RK. Strategies for limiting the side effects of
cancer pain therapy. Semin Oncol, 1997, 24:S16-28–34.
Martin WR. Pharmacology of opioids. Pharmacol Rev, 1983,
35:283–323.
Martin WR, Eades CG, Thompson JA, et al. The effects of
morphine- and nalorphine- like drugs in the nondependent and
morphine-dependent chronic spinal dog. J Pharmacol Exp
Ther, 1976, 197:517–532.
Matthys H, Bleicher B, Bleicher U. Dextromethorphan and
codeine: Objective assessment of antitussive activity in
patients with chronic cough. J Int Med Res, 1983, 11:92–100.
Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance
therapy versus no opioid replacement therapy for opioid
dependence. Cochrane Database Syst Rev, 2009,
CD002209.
McCleskey EW, Gold MS. Ion channels of nociception. Annu
Rev Physiol, 1999, 61:835–856.
McGinty JF. What we know and still need to learn about opioids
in the hippocampus. NIDA Res Monogr, 1988, 82:1–11.
523
CHAPTER 18
OPIOIDS, ANALGESIA, AND PAIN MANAGEMENT